Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets (2016 - 2026)

Ani Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $753.1 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 42.51% to $753.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $753.1 million, a 42.51% increase, with the full-year FY2025 number at $753.1 million, up 42.51% from a year prior.
  • Current Assets hit $753.1 million in Q4 2025 for Ani Pharmaceuticals, up from $698.4 million in the prior quarter.
  • Over the last five years, Current Assets for ANIP hit a ceiling of $753.1 million in Q4 2025 and a floor of $182.8 million in Q1 2021.
  • Historically, Current Assets has averaged $437.1 million across 5 years, with a median of $478.3 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 88.92% in 2021 and later fell 0.79% in 2025.
  • Tracing ANIP's Current Assets over 5 years: stood at $321.8 million in 2021, then increased by 6.99% to $344.3 million in 2022, then soared by 50.99% to $519.8 million in 2023, then increased by 1.66% to $528.5 million in 2024, then soared by 42.51% to $753.1 million in 2025.
  • Business Quant data shows Current Assets for ANIP at $753.1 million in Q4 2025, $698.4 million in Q3 2025, and $602.6 million in Q2 2025.